Cargando…
Coronary spastic angina after the administration of intravenous immunoglobulin in myasthenia gravis: a case report
BACKGROUND: Myasthenia gravis (MG) is an autoimmune disease caused by antibodies that block or destroy nicotinic acetylcholine receptors at the neuromuscular junction. Most of MG patients need immunosuppression agents in addition to treatments that alleviate the symptoms. Intravenous immunoglobulin...
Autores principales: | Yanagihashi, Masaru, Okamoto, Ryuichi, Morioka, Harumi, Sawada, Masahiro, Matsumoto, Shingo, Ikeda, Takanori, Kano, Osamu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453555/ https://www.ncbi.nlm.nih.gov/pubmed/32859168 http://dx.doi.org/10.1186/s12883-020-01901-2 |
Ejemplares similares
-
Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis
por: Díez-Porras, Laura, et al.
Publicado: (2020) -
Defects of CTLA-4 Are Associated with Regulatory T Cells in Myasthenia Gravis Implicated by Intravenous Immunoglobulin Therapy
por: Xu, Wenhua, et al.
Publicado: (2020) -
Management of Stable Angina with Ivabradine as Safe Alternative to Patients with Myasthenia Gravis
por: Ohde Dalledone, Giuliano, et al.
Publicado: (2016) -
Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis
por: Blaha, M., et al.
Publicado: (2010) -
Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
por: Kovács, Edina, et al.
Publicado: (2017)